Navigation Links
Cancer: Trapping the escape artist
Date:5/11/2010

ith one tenth the dose we had used with previous compounds," says Dr. Pellecchia.

BI-97C1 is currently licensed to Coronado Biosciences, a private, clinical stage biotech company focused on new cancer treatments. Coronado's pan Bcl-2 inhibitor program is expected to enter clinical trials soon. "We have a very productive collaboration with Dr. Pellecchia," says R.J. Tesi, M.D., president and CEO of Coronado Biosciences. "His work demonstrates the importance of inhibiting all six Bcl-2 pro-survival proteins and demonstrates how rational drug design can optimize the development of targeted therapies to treat cancer. We are anxious to move BI-97C1 from pre-clinical development into patients."


'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Prostate cancer: Watchful wait or vaccinate?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Stem cells and cancer: cancer pathways that also control the adult stem cell population
4. Hispanic women and breast cancer: An understudied group
5. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
6. Cancer: Another step towards medication
7. Early detection of lung cancer: New data presented at multidisciplinary meeting
8. From cars to cancer: UH professor employs auto industry tools for tumor therapy
9. Cancer: The cost of being smarter than chimps?
10. Cancer: Primitive gene discovered
11. Milk and risk of renal cell cancer: Genetic research sheds new light
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... mysteries of modern coral reefs is how they evolved from ... in the record of coral evolution. This evolutionary gap ... and changes in the Earth,s climate between 1 and 2 ... went extinct, and the modern reef corals emerged. To ...
... Bioinformatics Laboratory at the University of Illinois in collaboration ... probe the world of proteins for answers to questions ... formed from chains of amino acids and fold into ... sciences professor Gustavo Caetano-Anolls, very little is known about ...
... a new study carried out at the Norwegian Institute of ... supplements from four weeks before conception to eight weeks into ... birth to children with childhood autism (classic autism). "It ... before conception to eight weeks into pregnancy," states Pl Surn, ...
Cached Biology News:University of Miami geologists to address the mystery of an evolution gap in reef corals 2Untangling life's origins 2Untangling life's origins 3Folic acid lowers risk of autism 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Symbol: MS, EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), will hold,its Annual General Meeting ... 4:00,p.m. (ET)., A live audio webcast of the ... connect at least ten minutes prior to the,conference call ...
... Cequent Pharmaceuticals, a,pioneer in the development of ... and treat human disease, announced that Michael ... of directors. Dr. Taylor is,president and chief ... Massachusetts-based biotechnology company developing novel,classes of therapeutics ...
... Wednesday, May 7th at 9:30am EDT, NEW YORK, ... today announced that Michael S. Weiss, the Company,s,Chairman and ... Bank 33rd Annual Health Care Conference in Boston, Massachusetts., ... Wednesday, May 7th at,9:30am EDT, will be webcast live ...
Cached Biology Technology:BioMS Medical announces conference call and web cast for Annual General Meeting 2Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors 2Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference 2
Polio component type I...
... 'A New Concept in Microarrays: Biomedical ... chip technologies GmbH (Jena, Germany) have collaborated ... new CLONDIAG ArrayTube System. The DNAscope ... technology. The new DNAscope AT automatically reads ...
... AccuSpot automates LC micro-fractionation, spotting and ... AccuSpot system, LC eluent can be ... plates, in trace amounts. This allows ... for MALDI-TOF-MS measurements. When used in ...
... PF 2D is an automated, two-dimensional fractionation ... mixtures. Part of Beckman Coulters ProteomeLab ... results in just hours. The system ... in cell lysates, addressing a key challenge ...
Biology Products: